Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Only 4.5 months to go

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 14, 2021 4:23pm

151 Views

Post# 33205405

RE:RE:RE:RE:Only 4.5 months to go

GameChangerBet wrote:

YukonJezza wrote:
4.5 months to go before management can sell 1/2 of their new acquired shares

Dan won't be selling any shares, this was discussed during a meeting between him and myself last week.

Excellent - thanks for sharing GameChanger !

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security